Dental Tribune Europe
The Noble Biocare Xeal and TiUltra surfaces offer a novel surface chemistry and topography from the abutment to the implant apex. (Image: Nobel Biocare)

Nobel Biocare launches Xeal and TiUltra surfaces in US

By Nobel Biocare
January 27, 2021

YORBA LINDA, Calif., U.S.: Nobel Biocare is inviting dental professionals to join what it calls the Mucointegration era with the launch of its Xeal and TiUltra surfaces in the U.S. These new surfaces are applied to implants and abutments, optimizing tissue integration at every level.

New Xeal abutments feature next-generation surface chemistry designed to promote soft-tissue attachment. In a clinical study with a two-year follow-up, the Xeal surface demonstrated a significant increase in soft-tissue height compared with machined abutment surfaces. After its wide success and adoption in Europe, dental professionals in the U.S. will now be able to see and experience the pioneering Mucointegration surface as it is made available for Nobel Biocare’s On1 Base and Multi-unit Abutment.

The TiUltra surface promotes early osseointegration. The surface was developed for this purpose, as well as to support bone stability. With an ultrahydrophilic, multizoned implant surface, the TiUltra surface takes anodization technology one step further. Roughness, porosity, and surface chemistry are important factors for tissue integration. Surface chemistry, in particular, plays a vital role in enhancing cellular attachment.

TiUltra is now available for Nobel Biocare’s NobelActive, NobelParallel Conical Connection and NobelReplace Conical Connection implants. This combined with the Xeal abutment surface will give dental professionals a complete solution for tissue integration.

“Dental professionals are now able to experience the Xeal and TiUltra surfaces in their practice and discover how important the soft-tissue barrier becomes in protecting the underlying bone. It is this feature that promotes the basis for long-term tissue health and stability, which will be appreciated not only by the clinician, but by the patient as well,” said Patrik Eriksson, Nobel Biocare’s president.

Leave a Reply

Your email address will not be published. Required fields are marked *

© 2021 - All rights reserved - Dental Tribune International